Overview

Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b.i.d, compared to reduced dose during the first two weeks of treatment in a double-blind, randomized controlled parallel group comparison trial among Taiwanese patients with previous TIA's or ischemic stroke.To monitor frequency and intensity of headaches and other safety parameters among Taiwanese patients with previous TIA's or ischemic stroke given Aggrenox using a titration scheme or not
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Aspirin, Dipyridamole Drug Combination